Pretreatment pregnancy testing under iPLEDGE in 2026 must occur in a medical setting before your first isotretinoin dose. You need a screening test plus a second confirmatory negative test after 30 days of dual contraception or abstinence. iPLEDGE is the restricted safety program for isotretinoin, a drug for severe recalcitrant nodular acne. It requires enrollment by prescriber, pharmacy, and patient because even small fetal exposure carries severe risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How the two-test sequence works
- Where pretreatment tests must happen
- What the one-month preparation requires
- What the 2026 update changes
- What to do if you miss the pickup window
How the two-test sequence works
The sequence starts with a screening test when your prescriber decides to prescribe isotretinoin. You then use two approved contraception methods together, or remain continuously abstinent, for one full month.
The second test confirms a negative result after that month. It is timed to the menstrual cycle before therapy starts. Only then can the first dose proceed.
Where pretreatment tests must happen
All testing before the first dose must occur in a prescriber office, clinic, or laboratory. Home tests do not count at this stage, according to the FDA in the medical organizations letter. If the first dose has not been taken, any repeat test must still occur in a medical setting.
- Schedule both pretreatment tests at your clinic or lab
- Ask where results are recorded for iPLEDGE clearance
- Do not substitute a pharmacy-bought home test before dose one
What the one-month preparation requires
Patients who can become pregnant must use two iPLEDGE-approved contraception methods at the same time. The alternative is a commitment to continuous abstinence.
That protection covers one month before, the full treatment period, and one month after isotretinoin. The month-before period aligns with the interval between your two pretreatment pregnancy tests.
What the 2026 update changes
FDA approved iPLEDGE modifications on Feb. 9, 2026, with required implementation 180 days later on Aug. 9, 2026, according to the FDA REMS listing. The goal is lower burden with pregnancy safeguards retained.
The change removes the CLIA-certified-laboratory requirement and permits prescriber-approved at-home tests during and after treatment. Prescribers must have procedures to reduce misreading or falsification, as reported by Dermatology Advisor in their summary of FDA changes. Pretreatment stays in-clinic. At-home testing does not apply before the first dose.
What to do if you miss the pickup window
FDA removed the 19-day lockout after a missed 7-day prescription window. A patient who misses pickup can complete an immediate repeat pregnancy test without added waiting time.
That repeat test still follows pretreatment rules if treatment has not started. Contact your prescriber office promptly to schedule the medical-setting test and a new pickup date.
You Might Also Like
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: What Changed, What Did Not, and What Comes Next for Adult Acne Patients
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: A Source-Checked Briefing for Adult Acne Patients
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: What Changed, What Did Not, and What Comes Next for Adult Acne Patients